Lung Cancer and Thoracic Malignancies: Staging and Treatment Response.
Authors
Affiliations (2)
Affiliations (2)
- Department of Nuclear Medicine, Nigde Training and Research Hospital, Asagi Kayabasi, Hastaneler Caddesi, 51100 Merkez, Nigde, Turkey. Electronic address: [email protected].
- Department of Nuclear Medicine, Istanbul University, Topkapi, Turgut Ozal Millet Caddesi, Fatih 34093, Istanbul, Turkey.
Abstract
This article reviews the clinical role of 18F-fluorodeoxyglucose PET/ computed tomography (CT) in lung cancer and selected thoracic malignancies, focusing on staging and treatment response assessment, while emphasizing major interpretation pitfalls. In lung cancer, emphasis is placed on nodal and metastatic staging, evaluation for recurrence, metabolic response criteria, quantitative PET parameters, and treatment-specific imaging considerations. Selected applications in thymic epithelial tumors and malignant pleural mesothelioma are also discussed. Emerging approaches, including somatostatin receptor PET, fibroblast activation protein inhibitor PET, PET/MR imaging, and artificial intelligence-based PET/CT analysis, are briefly summarized.